Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Department of Research, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Clin Breast Cancer. 2019 Jun;19(3):165-177. doi: 10.1016/j.clbc.2019.01.006. Epub 2019 Jan 29.
Breast cancer is the most common cancer among women in the world. The aim of this study was to measure the global and regional survival rates of women with breast cancer. We searched Medline/PubMed, Web of Science, Scopus, and Google Scholar to identify cohort studies on the survival rate of women with primary invasive breast cancer until the end of June 2017. We used random effect models to estimate the pooled 1-, 3-, 5-, and 10-year survival rates. Subgroup analysis and meta-regression models were used to investigate the potential sources of heterogeneity. One hundred twenty-six studies were included in the meta-analysis. Between-study heterogeneities in the 1-, 3-, 5-, and 10-year survival rates were significantly high (all Is > 50%; P = .001). The global 1-, 3-, 5-, and 10-year pooled survival rates in women with breast cancer were 0.92 (95% confidence interval [CI], 0.90-0.94), 0.75 (95% CI, 0.71-0.79), 0.73 (95% CI, 0.71-0.75), and 0.61% (95% CI, 0.54-0.67), respectively. Subgroup analysis revealed that survival rates varied in different World Health Organization regions, age and stage at diagnosis, year of the studies, and degree of development of countries. Meta-regression indicated that year of the study (β = 0.07; P = .002) and development of country (β = -0.1; P = .0001) were potential sources of heterogeneity. The survival rate was improved in recent decades; however, it is lower in developing regions than developed ones.
乳腺癌是全球女性中最常见的癌症。本研究旨在测量女性乳腺癌的全球和区域生存率。我们检索了 Medline/PubMed、Web of Science、Scopus 和 Google Scholar，以确定截至 2017 年 6 月底关于女性原发性浸润性乳腺癌生存率的队列研究。我们使用随机效应模型来估计汇总的 1 年、3 年、5 年和 10 年生存率。亚组分析和荟萃回归模型用于研究潜在的异质性来源。126 项研究纳入荟萃分析。1 年、3 年、5 年和 10 年生存率的研究间异质性显著较高（所有 I2 > 50%；P =.001）。全球范围内，乳腺癌女性的 1 年、3 年、5 年和 10 年汇总生存率分别为 0.92（95%置信区间 [CI]，0.90-0.94）、0.75（95% CI，0.71-0.79）、0.73（95% CI，0.71-0.75）和 0.61%（95% CI，0.54-0.67）。亚组分析显示，生存率在不同世界卫生组织区域、诊断时的年龄和分期、研究年份以及国家的发展程度上有所不同。荟萃回归表明，研究年份（β=0.07；P=.002）和国家发展程度（β=-0.1；P=.0001）是异质性的潜在来源。近年来，生存率有所提高；然而，在发展中地区，生存率低于发达地区。
